Ligand Pharmaceuticals Inc. (LGND) Friday announced that its partner Novan, Inc. (NOVN) has submitted a New Drug Application FDA for berdazimer gel, 10.3% for the topical treatment of molluscum contagiosum.
Berdazimer gel, 10.3% could release nitric oxide and has anti-viral activity. It is poised to be a first-in-class topical treatment for molluscum, an infection caused by a poxvirus. The infection will result in a benign, mild skin disease characterized by lesions that may appear anywhere on the body.
For comments and feedback contact: editorial@rttnews.com
Business News